The University of Chicago Header Logo

Connection

Luciana Molinero to Middle Aged

This is a "connection" page, showing publications Luciana Molinero has written about Middle Aged.
Connection Strength

0.333
  1. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer. Appl Immunohistochem Mol Morphol. 2021 04 01; 29(4):258-264.
    View in: PubMed
    Score: 0.049
  2. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019 10 23; 7(1):274.
    View in: PubMed
    Score: 0.044
  3. A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). Int J Gynecol Cancer. 2024 Aug 05; 34(8):1140-1148.
    View in: PubMed
    Score: 0.015
  4. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. Br J Cancer. 2024 Sep; 131(5):820-831.
    View in: PubMed
    Score: 0.015
  5. The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. Gynecol Oncol. 2024 07; 186:17-25.
    View in: PubMed
    Score: 0.015
  6. Up-regulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis. Clin Immunol. 2003 Jan; 106(1):50-4.
    View in: PubMed
    Score: 0.014
  7. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. Clin Breast Cancer. 2021 12; 21(6):539-551.
    View in: PubMed
    Score: 0.012
  8. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021 06 10; 39(17):1842-1855.
    View in: PubMed
    Score: 0.012
  9. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 10 10; 396(10257):1090-1100.
    View in: PubMed
    Score: 0.012
  10. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020 11 01; 26(21):5631-5637.
    View in: PubMed
    Score: 0.012
  11. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):455-463.e4.
    View in: PubMed
    Score: 0.012
  12. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59.
    View in: PubMed
    Score: 0.011
  13. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clin Cancer Res. 2019 10 15; 25(20):6061-6072.
    View in: PubMed
    Score: 0.011
  14. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 08; 154(2):314-322.
    View in: PubMed
    Score: 0.011
  15. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol. 2019 03 01; 5(3):334-342.
    View in: PubMed
    Score: 0.011
  16. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 01 01; 5(1):74-82.
    View in: PubMed
    Score: 0.011
  17. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018 11 01; 29(11):2247-2253.
    View in: PubMed
    Score: 0.010
  18. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 11 29; 379(22):2108-2121.
    View in: PubMed
    Score: 0.010
  19. A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. Clin Pharmacol Ther. 2019 02; 105(2):486-495.
    View in: PubMed
    Score: 0.010
  20. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018 Nov; 140(2):317-328.
    View in: PubMed
    Score: 0.010
  21. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res. 2017 Sep 01; 23(17):5238-5245.
    View in: PubMed
    Score: 0.009
  22. Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers. PLoS One. 2016; 11(11):e0165856.
    View in: PubMed
    Score: 0.009
  23. Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. Transplantation. 2010 Sep 15; 90(5):540-6.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.